These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23579367)

  • 1. Evaluation of immunogenicity and safety of the new tetanus-reduced diphtheria (Td) vaccines (GC1107) in healthy Korean adolescents: a phase II, double-blind, randomized, multicenter clinical trial.
    Rhim JW; Lee KY; Kim SY; Kim JH; Kim HH; Kim HM; Choi YY; Ma SH; Kim DH; Ahn DH; Kang JH
    J Korean Med Sci; 2013 Apr; 28(4):586-92. PubMed ID: 23579367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of the new reduced-dose tetanus-diphtheria vaccine in healthy Korean adolescents: A comparative active control, double-blind, randomized, multicenter phase III study.
    Han SB; Rhim JW; Shin HJ; Kim SY; Kim JH; Kim HH; Lee KY; Kim HM; Choi YY; Ma SH; Kim CS; Kim DH; Ahn DH; Kang JH
    J Microbiol Immunol Infect; 2017 Apr; 50(2):207-213. PubMed ID: 26055693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase III Study to Evaluate the Immunogenicity and Safety of GC1107 (Adult Tetanus Diphtheria Vaccine) in Healthy Adults.
    Lee J; Choi JH; Wie SH; Park SH; Choi SM; Lee MS; Kim TH; Lee HJ; Kang JH
    J Korean Med Sci; 2019 Jan; 34(4):e31. PubMed ID: 30686952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of a single intramuscular dose of a diphtheria-tetanus toxoid (Td) vaccine (GC1107) in Korean adults.
    Lee S; Park WB; Shin KH; Ahn DH; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Vaccine; 2011 Oct; 29(44):7638-43. PubMed ID: 21864613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and Safety of a Newly Developed Tetanus-Diphtheria Toxoid (Td) in Healthy Korean Adolescents: a Multi-center, Randomized, Double-blind, Active-Controlled Phase 3 Trial.
    Choi UY; Kim KH; Lee J; Eun BW; Kim HM; Lee KY; Kim DH; Ma SH; Lee J; Kim JH
    J Korean Med Sci; 2021 Dec; 36(49):e313. PubMed ID: 34931494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a single intramuscular dose of a tetanus-diphtheria toxoid (Td) vaccine (BR-TD-1001) in healthy Korean adult subjects.
    Hong T; Chung YJ; Kim TY; Kim IH; Choe YK; Lee J; Jeon S; Han S; Yim DS
    Hum Vaccin Immunother; 2015; 11(10):2440-5. PubMed ID: 26091286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial [corrected] administration of tetanus toxoid (TT) versus tetanus and reduced diphtheria (Td) in pregnant women.
    Salama MM; Hady OA; Ashour W; Mostafa A; El Alkamy S; El Sayed N; El Yazeed RA
    J Clin Immunol; 2009 Jul; 29(4):524-31. PubMed ID: 19363703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of diphtheria-tetanus vaccine in adults.
    Choi JH; Choo EJ; Huh A; Choi SM; Eom JS; Lee JS; Park SH; Kang JH
    J Korean Med Sci; 2010 Dec; 25(12):1727-32. PubMed ID: 21165286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of a tetanus-diphtheria vaccine and a 13-valent pneumococcal conjugate vaccine after concomitant vaccination in ≥ 50-year-old adults.
    Song JY; Cheong HJ; Noh JY; Choi MJ; Yoon JG; Lee SN; Kang SH; Jeong EJ; Jo YM; Kim WJ
    BMC Infect Dis; 2018 Dec; 18(1):628. PubMed ID: 30518331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
    Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
    Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
    Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, or a month prior to or after, tetanus and diphtheria booster vaccinations.
    Southern J; Gelb D; Andrews N; Waight PA; Morris R; Cartwright K; Miller E
    Hum Vaccin; 2006; 2(6):237-42. PubMed ID: 17102644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.
    Pichichero ME; Rennels MB; Edwards KM; Blatter MM; Marshall GS; Bologa M; Wang E; Mills E
    JAMA; 2005 Jun; 293(24):3003-11. PubMed ID: 15933223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of diphtheria-tetanus vaccine in pre-adolescent and adolescent South Koreans.
    Lee SY; Kwak GY; Nam CH; Kim JH; Hur JK; Lee KY; Park JS; Kim HM; Kang JH
    Vaccine; 2009 May; 27(24):3209-12. PubMed ID: 19446193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines.
    Theeten H; Rümke H; Hoppener FJ; Vilatimó R; Narejos S; Van Damme P; Hoet B
    Curr Med Res Opin; 2007 Nov; 23(11):2729-39. PubMed ID: 17897485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced immunogenicity of diphtheria and tetanus toxoids when combined with pertussis toxoid.
    Trollfors B; Taranger J; Lagergård T; Sundh V
    Pediatr Infect Dis J; 2005 Jan; 24(1):85-6. PubMed ID: 15665717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and reactogenicity of a single dose of a diphtheria--tetanus--acellular pertussis component vaccine (DTaP) compared to a diphtheria--tetanus toxoid (Td) and a diphtheria toxoid vaccine (d) in adults.
    Bartels I; Jüngert J; Lugauer S; Stehr K; Heininger U
    Vaccine; 2001 Apr; 19(23-24):3137-45. PubMed ID: 11312009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
    Weston WM; Friedland LR; Wu X; Howe B
    Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.